• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Amarantus, RBCC target NuroPro Parkinson's diagnostic for joint venture

Amarantus, RBCC target NuroPro Parkinson's diagnostic for joint venture

October 10, 2012
CenterWatch Staff

Amarantus BioSciences, a Sunnyvale, Calif.-based biotech focused on brain-related disorders including Parkinson's disease and traumatic brain injury (TBI), and Rainbow Coral (RBCC), a biotech subsidiary Rainbow BioSciences, have selected NuroPro, Amarantus' Parkinson's disease blood test in development, as the target product candidate for the proposed joint venture.

"This is a cutting edge approach to diagnosing a debilitating disease that afflicts millions of people worldwide," said Patrick Brown, CEO of RBCC. "The marketplace is crying out for new breakthroughs in the diagnosis of neurological diseases, and we believe NuroPro has the potential to accurately diagnose people who suffer from Parkinson's disease, allowing physicians to initiate treatment regimens earlier, as well as conduct clinical research on disease-modifying treatments in development on a younger population of patients."

The deal is being structured to enable completion of the final stages of the NuroPro program, resulting in a commercially viable product to be introduced to the market place. The NuroPro test, which has completed phase I trials, works by measuring differentiated levels of biomarkers from blood serum in people who have Parkinson's disease.

The companies expect to initiate a phase II clinical study in 2013. The companies anticipate that upon successfully completing phase II, NuroPro will be introduced into the marketplace as a Laboratory Developed Test (LDT) in a Clinical Laboratory Improvement Amendment (CLIA) certified laboratory prior to initiating a regulatory process with the FDA.

"Our focus on Parkinson's disease has allowed us to gain considerable traction with partners who understand the potential value of the technologies we have in-house," said Gerald E. Commissiong, president and CEO of Amarantus. "This transaction will allow Amarantus to gain significant upside in revenues derived from the NuroPro asset while defraying the costs of the project in order to focus our internal resources on the MANF program for Parkinson's disease. As NuroPro advances towards commercialization, it could become a key competitive advantage for our MANF clinical development program."

The market for Parkinson's could grow to a value of $3.75 billion by 2015, according to a report last year by Visiongain analysts. RBCC expects a deal with Amarantus to help position the company to capitalize on that growth and generate revenue in the near-term. Amarantus expects a deal with RBCC to further enable the development of the MANF program.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • MachineLearning-360x240.png

    Industry Using AI/ML to Improve Data, Quality and Trial Management, Survey Says

  • VirtualTraining-360x240.png

    Virtual Training Evolves into More In-Depth Learning, Improved Communications

  • SurveywBlueBackground-360x240.png

    Mid-Study Updates Delay Trials At Least a Month, CSDD Report Finds

  • Real-TimeData-360x240.png

    Real-Time Data Helped Sponsors Respond to Sites’ Needs During the Pandemic

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing